Clinical Trial Update: A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating DSP-7888 Dosing Emulsion with Bevacizumab in patients with recurrent or progressive glioblastoma after initial therapy has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• DSP-7888 Dosing Emulsion

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Glioblastoma | Phase 3 | Status: COMPLETED | Results posted: 2023-01-30